Case Studygenerative aiclinical trialsastrazenecareal world evidence
AstraZeneca Deploys AI Clinical Trials Nationally
9.0
AstraZeneca is deploying AI clinical trials technology at national health-system scale, presenting CREATE study results at the European Lung Cancer Congress in March 2025. The study reported a 54.1% positive predictive value for its qXR-LNMS chest X-ray tool, after screening over 660,000 people in Thailand since 2022, and Thailand will scale the program across 887 hospitals with >415 million baht.
Key Points
- 1Deployed AI screens over 660,000 Thai patients since 2022, detecting suspected pulmonary lesions in 8%.
- 2Recorded 54.1% positive predictive value in CREATE study, far above the 20% predefined success threshold.
- 3Integrates generative AI across clinical operations to cut authoring time and enable virtual control groups.
Scoring Rationale
High novelty and industry-scale deployment, limited by single-company focus and regional concentration in Thailand pilot.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
